To study the dynamics of structural proteins in the heart, Vanderbilt investigators generated a cellular tool they expect will be useful for screening drugs that affect heart muscle contraction.

Vanderbilt neurologists have identified a protein modification that could be targeted to reduce neuronal excitability in epilepsy.

Aaron Wexler, PhD, a research fellow in the Department of Pathology, Microbiology and Immunology, has received a Helen Hay Whitney Foundation Fellowship.

The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.

Antiviral immunity, obesity and pulmonary fibrosis will be discussed by three Vanderbilt University researchers during a Cutting-Edge Discovery Lecture on Nov. 21. The lecture will begin at 4 p.m. in 208 Light Hall.

Gary Nabel, MD, PhD, Chief Scientific Officer and Senior Vice President of Sanofi, will deliver the next Flexner Discovery Lecture on Thursday, Nov. 14.